Bragar Eagel & Squire, P.C. Urges DexCom and Wildermuth Investors to Contact the Firm Regarding Their Rights

Core Viewpoint - Class actions have been initiated on behalf of stockholders of DexCom, Inc. and Wildermuth Fund, with deadlines for investors to petition the court to serve as lead plaintiff [1]. DexCom, Inc. (NASDAQ:DXCM) - The class action alleges that during the class period from January 8, 2024, to September 17, 2025, DexCom made materially false and misleading statements regarding its business and compliance policies [6]. - Specific allegations include unauthorized design changes to the G6 and G7 devices that rendered them less reliable, presenting health risks to users [6]. - The complaint claims that the enhancements to the G7 were overstated and that the true scope of issues with the devices was downplayed, leading to increased regulatory scrutiny and potential legal and financial harm [6]. Wildermuth Fund (NASDAQ:WEFCX, NASDAQ:WESFX, NASDAQ:WEIFX) - The class action for Wildermuth Fund covers the period from November 1, 2020, to June 29, 2023, with a lead plaintiff deadline of December 29, 2025 [6]. - Allegations include miscalculating the fair value of the Fund's investments and failing to disclose financial support for portfolio companies with questionable viability [6]. - The complaint also states that the Fund intentionally inflated its net asset value, resulting in excessive advisory fees, which harmed class members [6].